Symbols

ASRT

Assertio Holdings·NASDAQ

--(--)

Signals Analysis

Bullish signal 6

Bearish signal 1

Stock Price Surged Significantly

Consensus Rating "Strong Buy"

Ample Liquidity

High Gross Profit Margin

Revenue Beats Expectation

EPS Beats Expectation

RSI Overbought

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About ASRT

Assertio Holdings, Inc.

A specialty pharmaceutical company that develops prescription drugs focused on pain and central nervus system conditions and diseases

Industry

Pharmaceutical

Established Date

Listing Date

12/17/2003

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.assertiotx.com

Security Type

Common stock

Office address

100 South Saunders Road, Suite 300, Lake Forest, Illinois 60045

Business

Introduction

Assertio Holdings, Inc., is a pharmaceutical company with comprehensive commercial capabilities, providing differentiated products designed to meet the needs of patients. The company's focus is to support patients by marketing products primarily in oncology.

Company Financials

EPS

ASRT has released its 2025 Q4 earnings. EPS was reported at -1.06, versus the expected -0.07, missing expectations. The chart below visualizes how ASRT has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

ASRT has released its 2025 Q4 earnings report, with revenue of 13.54M, reflecting a YoY change of -57.92%, and net profit of -11.93M, showing a YoY change of -13.85%. The Sankey diagram below clearly presents ASRT's revenue sources and cost distribution.